| SUTRO BIOPHARMA NEW O.N. |
| USA |
| Gesundheit |
| US8693672011 / A41VMF |
| S090 (Frankfurt) / STRO (NASDAQ) |
| FRA:S090, ETR:S090, S090:GR, NASDAQ:STRO |
| - |
| https://www.sutrobio.com/ |
|
Sutro Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and manufacturing of next-generation protein therapeutics for oncology and immune-related diseases. Its proprietary cell-free protein synthesis..
>Volltext.. |
| 444.31 Mio. EUR |
| 524.26 Mio. EUR |
| 87.12 Mio. EUR |
| -82.99 Mio. EUR |
| -162.43 Mio. EUR |
| -19.25 EUR |
| 199.94 Mio. EUR |
| 49.41 Mio. EUR |
| -150.65 Mio. EUR |
| 1.88 |
| 45.59% |
| 25.95% |
| - |
| - |
| - |
| - |
| SUTRO BIOPHARMA, SUTRO BIO |
| 19.04.26 |
|